F8 and hemophilia A: <h4>Introduction</h4>Valoctocogene roxaparvovec, an adeno-associated virus (AAV)-based gene therapy, enables endogenous factor VIII (FVIII) expression in patients with severe hemophilia A without the need for regular FVIII infusions.